Ixekizumab exposure associated with myelitis: A case report and a literature review

Clara De Simone, Paolo Calabresi, Matteo Lucchini, Marina Romozzi, Simone Bellavia, Giacomo Caldarola, Marco Luigetti, Mario Di Filippo, Carlo Masullo, Massimiliano Di Filippo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

We describe a case of a 28-year-old man who developed a cervical myelitis while exposed to ixekizumab (IL-17 inhibitor) for psoriatic arthritis. Spinal MRI showed a T2 hyperintense lesion at the C4-C5 level while brain MRI was unspecific. Oligoclonal bands were absent and extensive screening for autoimmunity was negative. Rechallenge with ixekizumab was positive corroborating a relation between drug exposure and the neurological event. To the best of our knowledge, this is the first case of CNS inflammatory adverse event associated with ixekizumab. We also provide a review of case reports of demyelinating disorders associated with the use of biologic drugs for the treatment of psoriasis and psoriatic arthritis.
Lingua originaleEnglish
pagine (da-a)1-6
Numero di pagine6
RivistaJournal of Neuroimmunology
Volume2021
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Adult
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Arthritis, Psoriatic
  • Brain Mapping
  • CNS inflammation
  • Drug Substitution
  • Humans
  • IL-17
  • Immunologic Factors
  • Interleukin-17
  • Ixekizumab
  • Magnetic Resonance Imaging
  • Male
  • Myelitis
  • Paresis
  • Psoriatic arthritis
  • Spinal Cord
  • White Matter

Fingerprint

Entra nei temi di ricerca di 'Ixekizumab exposure associated with myelitis: A case report and a literature review'. Insieme formano una fingerprint unica.

Cita questo